THE WEAPONIZATION OF THE UNITED STATES GOVERNMENT AGAINST LAWRENCE J. GERRANS 

AND HIS PRIVATE ENTERPRISE


ABSTRACT

TARGETED: The Criminalization of Disruptive Innovation

How a Medical Innovator, His Company, and the Rule of Law Were Overtaken by an Undisclosed Federal Campaign


What This Is

A documented reconstruction of how a federal prosecution was preceded by a covert, intelligence style campaign - and how narrative control, psychological operations, and timeline concealment allowed it to proceed despite dispositive legal defects, constitutional, statutory and procedural violations.

This dossier documents how a founder-led medical technology company was effectively destroyed before adjudication, through a combination of undisclosed federal investigation, infiltration and internal disruption by intelligence-adjacent commercial agents (CIA & Foreign Services) illegally operating on domestic U.S. soil, narrative manipulation, regulatory choke points, financial incapacitation, legal obstruction, and post-indictment corporate capture - all while courts were denied the full investigative record necessary to exercise threshold gatekeeping, causing an Article III to function ultra vires and a collapse in the separation of powers.

This is not a dispute about evidence or guilt. It is a case study in process failure: how enforcement mechanisms, operating outside transparency and oversight, can substitute for adjudication and predetermine outcomes in free markets and private enterprise.


The Core Finding

The prosecution of Lawrence J. Gerrans and Sanovas, Inc. was foreclosed as a matter of law before it began due to authorized corporate governance. Yet it proceeded because the true investigative origins were concealed. The indictment was timed to trigger regulatory exclusion and create financial choke-out mechanisms to tortiously interfere with Mr. Gerrans companies and to incapacitate the defense and the enterprise pre-trial.  Pre-trial incarceration tactics and ineffective Trial Counsel established no investigation and brought no defense. The result was corporate and market destruction without judicial resolution.


If left unaddressed, this case establishes a precedent that authorizes the Executive Branch to infiltrate private corporations and intrude into private corporate boardrooms, criminalize unanimously authorized governance, and destroy enterprises through indictment alone.

 

How It Happened

1) A Visible Target with Institutional Exposure

Before founding Sanovas, Gerrans held senior leadership roles at multiple Fortune 500 Life Science companies and successfully advocated for major healthcare and securities legislation later enacted into law. His profile made him highly visible to industry, academics, institutions, regulators and policymakers well before any charging decision. That visibility matters: it explains why scrutiny could be intense - and why early actions would carry outsized consequences.

Compounding this exposure were documented allegations of conflicts of interest and misconduct involving the prosecuting AUSA, detailed in Administrative Procedures Act litigation (D.C. 1:26-cv-00170-LLA/1:24-cv-01252-UNA) and a civil RICO appellate record (CA9 24-6740). What is dispositive for oversight is not the allegation alone, but the absence of visible safeguards - no docketed recusal analysis, no recorded supervisory ethics review, and no threshold hearing addressing impartiality before indictment or trial.


2) The Rushed Indictment as a Regulatory Choke Point

The indictment issued while the founder was engaged in Wall Street fundraising. Mr. Gerrans was, quite literally, served with an indictment while on Wall Street conducting Sanovas, Inc.’s “Road Show”. The Government weaponized regulation to tortiously interfere in Sanovas, Inc. fundraising and Mr. Gerrans ability to afford his defense.

Under SEC securities laws and FINRA broker-dealer regulations, a company is precluded from raising monies in the public markets if a director or officer is under indictment, because a federal indictment creates probable cause that a crime was committed. Regardless of its veracity an indictment immediately disqualifies public-market fundraising, because it constitutes probable cause of criminal conduct. This effect is structural and foreseeable.

The timing of the indictment therefore functioned as a regulatory choke point: fundraising collapsed overnight; investors withdrew; counsel advised that continued capital formation was impossible unless and until the Founder stepped down from his Company and away from his Life’s work and the 250+ Multi-National Patents he assigned to his enterprise. The indictment punished before trial, foreclosing the company’s ability to stabilize operations or mount a defense to save itself and its founder.


3) Financial Incapacitation Before Adjudication

Beyond fundraising exclusion, the record reflects financial choke-out mechanisms commonly associated with white-collar enforcement: lis pendens filings that clouded assets, account freezes that halted operations, and de-banking (business, personal, family) without due process, and an entire year prior to any Trial, that impeded defense, cut off payment rails, and created undue financial hardship. Lawful in isolation, these measures combine pre-trial to immobilize an enterprise and defense - preventing investigation into a conflicted and corrupted prosecution, retention of counsel, counter-narrative capacity and harassing Mr. Gerrans, his family, employees and investors. Prosecution becomes academic when the subject cannot function.


4) The Investigation Began Years Earlier - and Was Hidden

Appellate filings (Ninth Circuit Case No. 24-6740, Dkt. 42.1) reveal that a large-scale FBI undercover investigation began in 2015, not 2017 - as misrepresented by the Government in multiple court filings. Nearly a dozen agents and informants were deployed; secret grand jury subpoenas were used; and a previously undisclosed 2015 Google subpoena seized the company’s entire email and governance repository in secrecy for years.

Critically, the Government already possessed exculpatory board authorizations that negated criminal intent and federal jurisdiction - yet those materials were not disclosed. Timeline control became narrative control; without it, suppression challenges and threshold dismissal would have been unavoidable.


5) Embedded Influence and Psychological Operations

The record further reflects embedded social and psychological operations inside the company’s ecosystem - conduct contemporaneously aligning with the FBI framework described by former agent Mike German, in his best-selling book, as “Disrupt, Discredit, and Divide – How the New FBI is destroying Democracy.”

Intelligence-experienced commercial actors, with publicly documented Foreign Intelligence Service, who infiltrated the company as Investors and Distributors of the company’s technologies, operated in close proximity to investors and employees through informal gatherings and trust-building forums, extracting sentiment, sowing doubt, and isolating leadership - before indictment and outside judicial oversight.

Following indictment, these embedded actors immediately filed civil litigation with narratives which mirrored criminal allegations, raising investigable questions about how pre-indictment influence operations echo into sworn claims. A former CIA employee was then placed on Sanovas, Inc.’s Board of Directors while other intelligence-experienced commercial actors were placed in advisory positions.


6) Post-Indictment Market Capture and IP Destruction

Once Mr. Gerrans was incapacitated, the company experienced a forced leadership transition under duress. Promised “rescuers” assumed influence at peak vulnerability. Fundraising at the parent company ceased; capital activity pivoted to a subsidiary under new governance; legacy investors were abandoned, employees were terminated, and the company’s state-of-the-art biotechnology facilities were shuttered, and the company’s remaining assets were moved into storage. The rescuers were in actuality corporate raiders implanted days before indictment.

Most consequentially, core patents were expired through non-payment of maintenance fees - an objective, verifiable loss of decades of innovation without court order or valuation. This is value transfer, intellectual property theft without adjudication.


7) A Systemic Convergence That Defeats Oversight

The case illustrates a broader pattern: intelligence methods, venture ecosystems, and prosecution converge in innovation environments, while oversight assumes clear boundaries that no longer exist. When investigative origins are concealed and financial exclusion precedes adjudication, no institution is positioned - or incentivized - to stop the process.


Why This Is a Story Now

Constitutional and due process safeguard mandate sunlight. The future of innovation and Free Enterprise weigh in the balance. Congress is holding hearings on the political weaponization of justice and the targeting of businesses and innovators. This case provides a documented, end-to-end example: concealed investigative origins, prosecutorial overreach, regulatory choke points, financial incapacitation, and market capture - all before courts can act.

The Company’s Board of Directors executed Unanimous Written Board Consents authorizing all corporate governance actions at issue, including retroactive ratification. Under settled corporate law, such consent extinguishes criminal intent and eliminates federal jurisdiction.

Despite this dispositive fact, the DOJ proceeded without standing anyway, weaponizing the Grand Jury process and inducing Article III courts to act ultra vires, resulting in a collapse in the separation of powers. The Ninth circuit then failed its gatekeeping duties, repeatedly insulating a conviction that should have never survived threshold review – raising serious questions of preservation through omission, if not outright institutional complicity. This case is the Canary in the Coal Mine.


What You Can Verify


Bottom Line

This is not about guilt nor law enforcement. This is about lawfare against free enterprise and innovation. This is about a broader systemic threat: The weaponization of criminal process to override corporate autonomy and punish disruptive innovation. This about how prosecutions survive by hiding how they began - and what that means for innovation, due process, and the rule of law.

The case demonstrates how process can replace adjudication - and how innovation in regulated markets can be criminalized by timing, concealment, and financial exclusion, not by proof. That is a question of public accountability, not personal grievance.

This abstract is intended to orient readers quickly. The full dossier provides documentation, timelines, and investigative leads for independent verification.


 

INVESTIGATIVE DOSSIER


TARGETED

THE CRIMINALIZATION OF DISRUPTIVE INNOVATION


How a Medical Innovator, His Company, and the Rule of Law Were Overtaken by an Undisclosed Federal Campaign


When Authorized Corporate Governance Is Criminalized

 

“If this stands, no Board Room in America is safe.”

 

SECTION I — THE MAN, THE MISSION, AND THE MOMENT HE BECAME A TARGET

How a Founder’s Life’s Work in Medicine and Finance Collided with Federal Power 

- and Why That Collision Demands Public Reckoning

I. Overview

This section examines why Lawrence J. Gerrans and Sanovas, Inc. became the subject of extraordinary scrutiny, culminating in a federal prosecution later shown to be jurisdictionally defective. It does not allege motive. It establishes context, incentives, and visibility - the conditions under which scrutiny predictably arises.

Investigative reporting begins not with guilt or innocence, but with target selection. Why this individual? Why this company? Why at this moment?

The record shows that Lawrence J. Gerrans was not a peripheral executive or a marginal entrepreneur. He was a founder-inventor operating at the intersection of medicine, finance, intellectual property, legislation and regulation, advancing models through patent protections, legislative victories, institutional alliances and execution tactics that disrupted entrenched business and capital structures in highly sensitive industries.

That combination - disruption plus visibility plus regulated markets - is historically associated with heightened enforcement attention, irrespective of wrongdoing.


I.1. Not a Typical Executive - A Builder of Systems, Not Schemes

Before he became a criminal defendant, Lawrence J. Gerrans was something else entirely: a recognized innovator, prolific inventor, and corporate builder - an executive whose career trajectory and public work were premised on a simple wager: that American institutions still reward lawful invention, disciplined governance, and civic engagement.

Gerrans’ profile does not resemble the archetype of the “white-collar criminal” constructed in press releases: marginal actors, opaque shells, and opportunistic fraud. He was a senior Fortune 500 executive with major corporate experience, a visible presence in policy circles, and a founder whose identity was inseparable from the enterprise he built. His innovations spanned medicine and finance, domains where a breakthrough does not merely compete - it threatens entrenched economic models.

Gerrans work was not confined to private ventures. It was publicly documented, academically examined, and institutionally engaged:

“How to build a $710 million Bio-Technology Company in Silicon Valley … without Silicon Valley ~ The Gerrans Chronicle”, 

placing his methods squarely within mainstream policy and innovation discourse.

This matters because it establishes that Gerrans’s activities were visible, legible, and known - to investors, regulators, legislators, academics, the industry and, inevitably, enforcement agencies.

Visibility is not wrongdoing. But in high profit, regulated industries, visibility changes risk. This matters    because it forces the first investigative question that dominates this entire saga:

Why would a founder with a public track record, a high-profile legislative footprint, and extensive corporate governance authorization be treated as a criminal target rather than a civil dispute participant?

The answer begins with what Sanovas represented.

 

I.2. Sanovas Was Not a Startup. It Was a Life’s Work.

Sanovas was built around a founder’s personal intellectual capital: hundreds of inventions, patents, and trademarked technologies, assigned into the company as the core asset base. This is not unusual in innovation-driven enterprises; it is how breakthroughs move from individual insight to scalable product.

But it creates a unique vulnerability: when the founder is removed - by scandal, by indictment, or by institutional isolation - the company does not merely lose leadership. It loses its animating force, its technical continuity, and its narrative legitimacy with markets.

Gerrans has described Sanovas as his “life’s work.” The record supports that framing in a way that people understand intuitively: when an enterprise is built from the founder’s IP assignments, professional credibility, and policy momentum, the founder is not a replaceable officer. He is the gravitational center. He IS the Life Force.

That fact made the company exceptionally valuable. It also made it exceptionally fragile.

Sanovas was not conceived as a conventional medical device company. It was structured as a life-science accelerator, designed to:


From an investigative perspective, five (5) aspects of Sanovas are particularly salient.


A. Curative Technologies in Disease-Management Markets

Sanovas’s focus on early detection and cure - particularly in oncology - challenged dominant healthcare business models built around long-term disease management. Historically, curative innovations have faced resistance not only from scientific skepticism, but from economic incumbency. This is not conjecture. The healthcare industry’s structural incentives are well documented: treatments that reduce lifetime utilization disrupt revenue streams tied to chronic care.

Sanovas’s technologies, as reflected in patent filings and public descriptions, directly implicated this tension. Gerrans partnerships and corporations to cure Lung Cancer, Colon Cancer, Diabetic Retinopathy, Asthma, Mesothelioma, and High Blood Pressure, alone, were disruptive to over $100 Billion in annual revenues. His initiative to cure Mesothelioma threatened billions of Dollars in Legal Defense Funds.

Sanovas and Gerrans were Bonafide, indisputable, and legitimate threats to the profits of established markets and their profiteers in Big Money and Dark Pharma; as well as the Deep State actors in our government and others who protect these interests.

 

B. Platform IP and Portfolio Structures

Rather than monetize individual devices, Sanovas pursued a portfolio model, licensing technology into multiple procedure-specific entities. This approach concentrated intellectual property control while decentralizing commercialization. Such corporate trust-like structures are lawful and common in venture innovation. They are also less familiar to traditional enforcement frameworks, which often assume linear corporate hierarchies and conventional operating companies. Novel structure invites misunderstanding - and, at times, suspicion.


C. Global Collaboration

Gerrans entered Sanovas into hundred-million-dollar research, development, and distribution relationships with international partners, including academic institutions and commercial entities abroad. These relationships were documented through contracts and joint ventures, not informal arrangements.

Global reach does not imply impropriety. But in the post-9/11 regulatory environment, international business activity in sensitive technologies often attracts additional scrutiny, particularly when combined with advanced medical devices and capital flows. Gerrans inventions were so advanced that even DARPA and BARDA invited him to disclose and discuss his tech with them. 


D. Financial Innovation: Disrupting Capital Formation

Sanovas did not rely exclusively on traditional venture capital pathways. Instead, Gerrans pioneered and advocated alternative capital formation models for early-stage medical technology companies - models later reflected in legislative reforms.

Key features included:

These activities were not hidden. They were studied, debated, and ultimately normalized through legislation. But prior to that normalization, they occupied a contested regulatory space which Gerrans navigated and reformed. From an investigative standpoint, this is critical. Regulatory gray zones - especially when navigated publicly and at scale - often become enforcement flashpoints, even absent fraud.


E. Intersection with Intelligence-Linked Commercial Actors

The record reflects that William Gleason, a former foreign-intelligence operative, became involved in the Sanovas ecosystem both as an Investor and through commercial distribution arrangements he initiated with Cellmark AB, a Swedish company operating through subsidiary companies in the United States (Cellmark Medical), the United Kingdom (Cellmark International) and Thailand Cellmark Siam LTD) – among other jurisdictions.

The following facts are documented:

The contracts exist. The litigation exists. The intelligence background(s) exists.

What is not explained in the public record is how this intersection was evaluated - if at all - by prosecutors or investigators, or how intelligence-linked commercial participation may have shaped investigative narratives and/or were used to influence FISA Courts to obtain subpoena’s and warrants into Sanovas entire repository of corporate documents, data and e-mails at Google, into cellphone records at AT&T, into the procurement of cell signal interceptors (Triggerfish), into internet service providers, and others.  

Despite the obvious, this dossier does not assert coordination or conspiracy. It identifies an unanswered intersection that investigative journalists are well positioned to examine.


I.3. A Founder Empowered by Governance - and Why That Authorization Is Central to “WHY”

Unlike the caricature of a founder operating beyond governance, Gerrans’ role was explicitly structured through corporate action:

These facts do more than answer “who had authority.” They expose the larger “WHY” question:

If governance authorization was real, documented, and approved, what explains a federal campaign that storm-trooped into a private company and treated authorized governance as a criminal premise?

The answer is not only legal. It is structural.

 

I.4. Disruption Economics: When “Cure” and “Capital Access” Threaten Entrenched Power

In healthcare, breakthrough technologies do not merely compete with products; they compete with revenue models. “Disease management” economics - recurring treatment, chronic care pipelines, reimbursement cycles - are structurally threatened by disruptive technologies that aim at curative outcomes or radically improved detection and intervention.

In finance, disruptive capital formation threatens a different kind of incumbency: gatekeepers. When a founder helps expand pathways for capital formation - crowdfunding, retail access, democratized investment structures - the beneficiaries are innovators and investors outside traditional networks. The displaced are intermediaries. Gerrans model of equity crowd funding forever changed the landscape of capital formation. More importantly, it stripped the gatekeepers of their control and returned it to the Free Markets.   

Gerrans’ profile placed him in both crosshairs simultaneously:

This dual-disruption profile explains why the narrative environment around him became combustible. It also explains why this dossier cannot be a sterile recitation of chronology: the surrounding incentives are what make the conduct, profiled in Sections III–V, plausible and urgent.


A. Narrative Vulnerability in a Post-Enron Enforcement Culture

By the time of the prosecution, white-collar enforcement culture had shifted decisively toward narrative-driven cases. Complex business structures, founder control, novel financing, and global activity are often reframed - implicitly or explicitly - as red flags.

In such environments, authorization becomes “control”, Innovation becomes “evasion”, and novelty becomes “deception”. Once that reframing occurs, indictment itself performs the regulatory work, irrespective of adjudication. This dynamic does not require bad faith. It arises from institutional incentives, risk aversion, and the political economy of enforcement.

This case is a direct byproduct of the regulatory correctives implemented post-Enron. At the root of the Governments case is a false claim that Gerrans withdrew accrued and deferred compensation he was not authorized to withdraw. Incredibly, Gerrans authorization to withdraw his accrued and deferred compensation was derived directly from an IRS 409(a) Regulatory mandate requiring deferred compensation be paid out within strict timeframes post award, lest the corporation and the executive incur withholdings and penalties in excess of 20% of the amounts due and owing the executive.

This IRS 409(a) Tax Law was created in 2005 to specifically address the, otherwise legal, conduct which occurred in the midst of Enron’s collapse and its executive’s withdrawing years of their deferred compensation. Here, the Government used regulatory compliance to allege criminalization by Gerrans.

 

I.5. The Rushed Indictment: A Known Regulatory Kill Switch

Once federal prosecutors secure an indictment against a director or officer, a predictable chain of consequences follows. This is not merely reputational. It is regulatory.

As counsel explained to Gerrans at the time, public-market fundraising becomes effectively impossible once an officer is indicted, because an indictment is a formal finding of probable cause, it triggers mandatory disclosure obligations, it renders offerings non-viable, it freezes counterparties and investors.

This is why indictment timing matters. It is also why the “WHY” question is inseparable from mechanism. If Gerrans was on Wall Street raising capital - the lifeblood for a founder-led technology enterprise - then an indictment at that moment does not merely initiate prosecution. It activates a kill switch that: collapses fundraising, triggers calls for resignation, and fractures stakeholder confidence.

You do not need conspiracy to see strategy. You only need institutional awareness of predictable effects.

Here, the Government is proven to have weaponized SEC Securities Laws and FINRA Regulations to time an indictment to tortiously interfere with Sanovas and Gerrans Fundraising – because according to SEC Laws and FINRA Regulations a company is barred from raising monies in the Public Markets if its Director or Officer is indicted, because a Federal Grand Jury Indictment creates probable cause that a crime was committed. 

Thus, we evidence regulation strategically purposed as a Kill Switch.


I.6. Financial Incapacitation: When “Process” Becomes Punishment

Indictment does not operate alone. In many white-collar prosecutions, the subject experiences pre-trial financial incapacitation through mechanisms that are lawful individually but devastating in combination:


These are often described as collateral consequences. In practice, they become the enforcement instrument. Here is why this matters: 

A defense cannot be mounted, and a company cannot survive, without money and continuity. When financial rails are cut off, the system doesn’t need a conviction to destroy the target. The destruction occurs in the gap between indictment and adjudication.

This is not merely a human story. It is a governance story for America’s innovation economy. The Federal Governments leveraging of an indictment to exact regulatory roadblocks to financially destroy an enterprise and a defendant’s affordability of his defense, prior to any due process, is why, in part, federal jurisdiction was foreclosed and jurisdiction cannot attach.

This case evidences the broader systemic threat: The weaponization of federal criminal process to override corporate autonomy and punish innovation. 


I.7. The Prosecutor as a Subject of Oversight: Conflicts and the Absence of Visible Safeguards

The Civil RICO appellate record alleges conflicts of interest and misconduct involving the prosecuting AUSA. That record’s claims - whatever their ultimate adjudication - place a spotlight on a more foundational oversight failure: the absence of visible safeguards and transparency mechanisms that should govern prosecutors in high-impact cases.

Readers should ask:


If a case implicates complex state-law governance, enormous market consequences, and coercive pre-trial effects, the absence of clear conflict review is not a footnote. It is a central “WHY.”


I.8. The Constitutional Dimension: Innovation as a Protected Interest

There is a deeper constitutional layer here that most audiences overlook until it is plainly stated: innovation is not merely commercial. It is contemplated by the Constitution itself.

Article I, Section 8, Clause 8 “authorizes Congress to secure exclusive rights to inventors for limited times”. That clause reflects the premise that invention is a public good and that its commercialization and protection are central to American progress.

In founder-led enterprises built on patented inventions, government action that dislocates an inventor from his Patents and removes the inventor from the market - especially through a process later shown to be jurisdictionally defective - does not merely affect a company. It affects the constitutional policy that invention should be fostered rather than extinguished by state force.

This is not rhetorical flourish. It is the moral center of why this story resonates beyond one man’s case.


I.9. The Moment the Story Turns: When Scrutiny Becomes a Campaign

At this point, the dossier transitions from “a hard case” to “a systemic warning.”

Because Section III will later establish (through CA9 24-6740, Dkt. 42.1) that:


The prosecution did not begin with indictment. 

The campaign began years earlier, and the indictment was only the public face of a covert process already in motion.

That is the pivot.


I.10. Carceral Incapacitation: Detention, Isolation, and the Erosion of the Right to Defend ~ the weaponization of “Diesel Therapy”.

When a Prosecution That Should Not Exist Becomes Its Own Punishment

Detention is often discussed as a collateral feature of criminal prosecution. In cases where guilt is genuinely disputed and jurisdiction is secure, that framing - though still troubling - may suffice. But in a prosecution that was foreclosed as a matter of law, detention is no longer collateral. It becomes the primary enforcement mechanism.

This section examines how detention, transfer, and isolation functioned not merely as conditions of confinement, but as structural forces that impaired the defense of an innocent person.


A. Detention as Consequence, Not Adjudication

In the Gerrans case, detention followed indictment - not conviction. This distinction matters.

Under constitutional design:

Yet in practice, detention exerts immediate and irreversible effects:


In a case where the conduct was board-authorized and therefore lawful, the effect of Pre-Trial detention imposed punishment without adjudication. In Gerrans case the punishment was severe.

 

B. Transfers and the Destruction of Defense Continuity

Following arrest, Mr. Gerrans was transferred repeatedly between detention facilities, subjected to deplorable conditions of confinement, found Rat Feces and Bird excrement in his Food Trays, denied medications, contracted a MRSA Flesh Eating Virus as well as the COVID Virus and exposed to incredible violence. According to the docket, record, civil lawsuits and contemporaneous writings, these events and transfers occurred during critical litigation periods.

From a defense perspective, repeated transfers matter because they:


In investigative terms, this is not about comfort. It is about functional impairment. A defense cannot be mounted in fragments.


C. Isolation and Restrictive Housing

The record reflects prolonged periods of isolation and restrictive housing classifications. Mr. Gerrans was silenced and dis-communicated by the Government via subjection to 16 institutional transfers in 33 months - California to Nevada, Oklahoma, Michigan, Texas, Arizona and back. He endured over 780 days in solitary confinement. This was an unprecedented regimen of abuse.

Isolation has predictable effects:


For an accused person attempting to defend against a complex white-collar prosecution - especially one involving intricate corporate governance and jurisdictional arguments - these effects are not incidental. They are case-shaping.


D. “Diesel Therapy” as a Descriptive Framework

The pattern of repeated transfers and isolation resembles what defense lawyers and oversight bodies commonly refer to as “diesel therapy.” The term does not imply intent. It describes a phenomenon:


Used in this descriptive sense, the term helps journalists understand how defense impairment can occur without any single abusive act.

Mr. Gerrans was subjected to one of the most harrowing cases of pre-emptive and retaliatory detention, isolation and transportation ever recorded. 

The regimen of “Diesel Therapy” he was subjected to is among the worst on record.

The endurance over 780 days of solitary confinement, in the midst of 16 institutional transfers over 33 months (during the COVID crisis and despite National Lock-Down directives) denied critical access, communications and coordination essential to his defense – and placed Mr. Gerrans at grave and undue risks. Mr. Gerrans trial and appellate process were forever disrupted. He was continually denied the ability to review the Discovery in his own case. Opportunities to bring the truth and evidence forward were lost.

This dossier does not allege a directive or conspiracy. It documents effects.

The combined effect of pretrial detention conditions, repeated transfers (during COVID and in defiance of National Lockdown Orders), restricted access to counsel, and prolonged isolation served to psychologically and physiologically decondition Mr. Gerrans and materially impaired his ability to participate in his own defense.


E. Contemporaneous Documentation: The Innovator Behind the Iron Mask

Mr. Gerrans documented his detention conditions contemporaneously in writings later compiled as The Innovator Behind the Iron Mask. These writings are significant not because they are literary, but because they are: contemporaneous, dated, internally consistent, and corroborative of known detention dynamics

They describe prolonged isolation and enforced idleness, exhaustion from transport, and disrupted communication with counsel and family. For journalists, these writings function as primary-source material, analogous to prison diaries or contemporaneous logs used in other investigations.


F. Sixth Amendment Implications

The Sixth Amendment guarantees not only the right to counsel, but the meaningful ability to consult with counsel and participate in one’s defense. When detention conditions prevent sustained attorney-client consultation, disrupt review of evidence, or impair cognitive functioning, the right to counsel becomes hollow.

In the Gerrans case, these impairments are particularly consequential because the defense hinged on legal arguments - authorization, jurisdiction, federalism - not merely factual disputes. A defendant deprived of the ability to access evidence exculpatory to his innocence, think, communicate, and prepare is effectively disarmed in such a case.


G. Why Detention Completed the Enforcement Cycle

Viewed in isolation, detention can be rationalized as administrative necessity. Viewed in context, it completes a cycle:

At no point in this cycle is guilt adjudicated in a manner consistent with constitutional design. For journalists, this is the crucial insight: Detention did not follow guilt. It substituted for it.


H. Why This Matters Beyond One Defendant

The implications extend far beyond Mr. Gerrans. If:

then innocence becomes a theoretical concept rather than a practical protection. This is not a flaw in a single jail or a single case. It is a systemic vulnerability. Pre-Trial and Appellate detention are tools of the system.


I.11. Why Section I Matters to Editors and Legislators

Section I is not a biography. It is an orientation.

It is intended to inform editors and legislators how to read everything that follows:

These conditions create a predictable risk profile - not of criminality, but of targeting.

The question for investigators is not whether disruption should be criminalized. It is how systems respond when disruption collides with power.

This combination creates a case that is not merely “wrongful,” but structurally dangerous:

If indictment and concealed investigation can remove an inventor from the market, collapse capital access, and destroy IP before courts act, then the rule of law becomes optional in innovation economies.

If left unaddressed, this case authorizes the Executive Branch to intrude into private corporate boardrooms, criminalize unanimously authorized governance, and destroy enterprises through indictment alone.

These are the “WHY.” And it is why this story belongs on the national stage now.


Transition to Section II

“Disruption, Incumbency, and the Economics of Resistance in Healthcare.”

Having established who the target was and why the target was visible, the next section examines how economic disruption translates into institutional resistance - specifically, the healthcare industry’s incentive structures and the documented pattern of suppressing curative innovation.

Section III will show what this machinery does once activated:

How leadership displacement occurs under duress, how capital is rerouted, how patents lapse, how enterprises are captured, and how value is transferred without adjudication - while the founder is isolated from markets, counsel, and credibility.

 

SECTION II

DARK PHARMA & MARKET INCENTIVES

How Curative Innovation Collides with Disease-Management Economics


II.1. Overview

Section I established who the target was and why that target was visible: a founder-inventor operating at the intersection of medicine, finance, intellectual property, public policy and regulation. Section II examines why that visibility mattered economically.

This section does not allege wrongdoing by industry actors. It examines documented incentive structures within healthcare markets - particularly the tension between curative technologies and chronic disease-management business models - and how those incentives shape resistance, scrutiny, and outcomes when disruptive innovation emerges.

Investigative reporting routinely begins here: not with intent, but with who benefits from the status quo and who bears risk when it is disrupted.


II.2. Disease-Management Economics: The Dominant Model

For decades, the modern healthcare economy has been built around recurring utilization. Chronic disease management - ongoing diagnostics, maintenance therapies, repeat procedures, and lifetime drug regimens - creates predictable revenue streams across manufacturers, distributors, providers, and payors.

This is not controversial. Industry financial statements, analyst coverage, and reimbursement frameworks openly reflect it. In such an environment, curative interventions - particularly those that prevent downstream utilization - pose a structural challenge. A cure collapses future demand. Early detection eliminates advanced-stage treatment. One-time intervention competes against recurring revenue.

The consequence is not a coordinated response, but a systemic bias: markets reward therapies that extend utilization more reliably than those that eliminate it. The investigative inquiry is: Are these market forces morally and ethically welcome in a responsible, health conscience and economically vulnerable society?

Mr. Gerrans answer was no. He resisted the market forces. In a master class of intellectual judo, he used their strength against them and changed both the Medical and Financial paradigm they were leveraging against society and government. He was punished for “disrupting the Eco-system”.

 

II.3. Curative Innovation as an Economic Disruptor

Sanovas’ technology portfolio - reflected in patent filings, platform descriptions, and public statements - was oriented toward early detection, precision intervention, and curative outcomes, particularly in oncology and pulmonary medicine. From an economic perspective, such technologies:

Investigative reporters have long documented similar dynamics in other sectors: disruptive technologies are often resisted not because they fail, but because they work too well. This resistance rarely takes the form of explicit opposition. More often, it appears as:


II.4. Capital Gatekeepers and the Cost of Nonconformity

Healthcare innovation does not exist in isolation. It depends on capital - often from concentrated gatekeepers who are themselves embedded in the prevailing business model.

Lawrence Gerrans approach to capital formation departed from conventional venture pathways. As established in Section I, Lawrence Gerrans explored and advocated alternative financing mechanisms, later studied academically and reflected in policy reform.

Before such reforms were normalized, however, these approaches occupied a contested space. Innovators who circumvent traditional capital channels may reduce dependency - but they also lose protection. When disputes arise, they lack the buffering influence of entrenched institutional sponsors.

From an investigative standpoint, this matters because capital alignment often shapes narrative alignment. Innovators outside traditional networks are more exposed when scrutiny intensifies. In Mr. Gerrans case he was told in no uncertain terms, “If you continue to bring us recurring revenue opportunities you will remain welcome. But if you keep trying to act like a Superhero and cure shit, you will not. In fact, you will be Black-balled.”

So, Mr. Gerrans mustered the American Spirit, acted “like a Superhero” and proceeded to “cure shit”. But he did not stop at defiance. Mr. Gerrans devised a winning strategy to entirely change the “ecosystem” in capital formation and proceeded to quietly and effectively execute the demise of Big Money’s Bully pulpit.

 

II.5. “Dark Pharma” as an Analytical Frame

The term “Dark Pharma,” as used in prior writings and commentary, is best understood not as an accusation, but as an analytical shorthand for the shadow side of market incentives in healthcare.

It refers to:

These dynamics are documented across academic literature, investigative reporting, and industry analysis. They do not require secret coordination. They emerge organically from profit-maximizing systems. Using this frame allows investigators to ask the right questions without asserting answers.


II.6. When Market Incentives Meet Enforcement Power

Market resistance alone does not explain the escalation from scrutiny to prosecution. That escalation occurs when economic incentives intersect with enforcement authority - often indirectly.

In highly regulated industries, regulators and prosecutors rely on industry expertise to understand complex technologies. That reliance can subtly shape investigative focus, framing, and prioritization. Again, this does not imply improper influence. It reflects structural dependence. But it does mean that industry narratives - including skepticism toward curative disruption - can migrate into enforcement contexts. Once that migration occurs, innovation risk becomes criminal risk.


II.7. Beneficiaries of Market Reversion

When a disruptive enterprise collapses, markets do not remain neutral. Value redistributes. In Sanovas’s case, the record reflects that:

Investigative reporting asks a simple question at this stage: Who benefits when disruption stops?

The answer is rarely singular. It is structural. Incumbent models persist. Capital flows revert. Risk dissipates.

 

 

II.8. Why Incentives Matter Even Without Intent

A central insight of investigative economics is that incentives operate independently of intent. Systems produce outcomes even when no individual actor seeks them. Thus, the relevance of market incentives in this dossier is not to assign blame, but to explain plausibility: why extraordinary scrutiny, resistance, and escalation can occur in the absence of proven wrongdoing. This is the “why” that complements the “so what.”


II.9. Investigative Significance

For journalists, Section II suggests concrete lines of inquiry:

These questions are answerable - and publishing them advances public understanding.

SECTION III

NARRATIVE WARFARE & FBI FRAMEWORKS

How Scrutiny Becomes Story - and Story Becomes Leverage


III.1. Overview

Sections I and II established who was targeted and why powerful market incentives made that target vulnerable. This section examines how the investigation itself unfolded, and how control of the narrative - particularly control of the investigative timeline - became central to sustaining the prosecution.

Newly disclosed appellate materials in Ninth Circuit Case No. 24-6740, Dkt. 42.1 (and Docket Numbers 477, 501- 517 in the underlying criminal case 3:18-cr-00318-EMC) fundamentally alter the understanding of this case. They demonstrate that the Government’s public and litigated timeline of investigation was materially false, and that a covert, intelligence-style investigative campaign was underway years earlier than represented. This section documents that campaign using the Government’s own exhibits.


III.2. The Official Narrative - and Its Collapse

Throughout trial and post-conviction proceedings, the Government represented that its investigation into Lawrence J. Gerrans and Sanovas, Inc. began in or around 2017, framing the case as a conventional response to alleged misconduct.

DKT 42.1 dismantles that narrative.

Exhibits 4 through 11 establish that by 2015, the Government had already deployed:

This was not a preliminary inquiry. It was a full-scale undercover operation, conducted two years earlier than disclosed, and entirely inconsistent with the Government’s representations to the defense, the court, and post-conviction counsel. For investigative journalists, this is not a technical discrepancy. Timeline control is narrative control.


III.3. The 2015 Blitzkrieg: Exhibits 4–11

The materials attached to DKT 42.1 reveal a coordinated, multi-pronged campaign beginning in 2015 that bears hallmarks more commonly associated with intelligence operations than routine white-collar investigations.

According to the exhibits:

This approach aligns with what investigative reporting has described as parallel construction: evidence is gathered covertly, then later laundered into a sanitized narrative that obscures its origin.


III.4. The Google Subpoena: Exhibit 13 and the Suppression of Exculpatory Evidence

Perhaps the most consequential revelation in DKT 42.1 is Exhibit 13, which documents the Government’s use of a previously undisclosed grand jury subpoena to Google in 2015.

That subpoena compelled Google to produce:

The defense was never informed of this subpoena. Post-conviction counsel was affirmatively misled about its existence. From an investigative standpoint, this raises stark questions:

This is not a discovery dispute. It is a structural failure of disclosure tied directly to timeline concealment.


III.5. Narrative Warfare as an Operational Necessity

Once the true investigative timeline is revealed, the role of narrative warfare becomes clearer. If the Government had disclosed in 2017 that:

the prosecution’s legitimacy would have been immediately questioned.

Narrative compression - presenting the case as a late-arising response to wrongdoing - was not incidental. It was necessary to sustain momentum, avoid suppression challenges, and prevent early judicial intervention.

This dynamic tracks precisely with the “Disrupt, Discredit, and Divide” framework described by former FBI agent Mike German in his Best Selling novel - not as a conspiracy, but as an institutional pattern that emerges when enforcement action outruns legal sufficiency.


III.6. Disruption, Revisited: Operational Consequences of Concealment

The concealed 2015 investigation explains several downstream effects that were previously treated as coincidental:

Disruption did not begin with indictment. It began years earlier, quietly, and without the safeguards that accompany open judicial proceedings.


III.7. Why the Timeline Had to Stay Hidden

Investigative journalism teaches that when timelines are manipulated, motive is often structural rather than personal. Here, disclosure of the true timeline would have:


In short, the case could not survive transparency.


III.8. Relationship to the Broader Pattern

Section III now bridges the gap between context (Sections I–II) and causation:


This is no longer theoretical. It is documented.


III.9. Investigative Questions Raised by DKT 42.1

This section frames concrete, answerable questions for reporters and oversight bodies:

These are not rhetorical questions. They are investigative leads.


III.10. Transition

With the investigative timeline now exposed, the next section examines how intelligence-linked commercial actors intersected with this covert campaign - and why that intersection deepens the unanswered questions rather than resolving them.

SECTION IV will examine:

“The Cellmark Infiltration: Commercial Embedding, Civil Litigation Echoes, and Intelligence Proximity.”


 

SECTION IV

THE CELLMARK INFILTRATION & PSYCHOLOGICAL OPERATIONS

Commercial Embedding, Social Manipulation, and the Mechanics of “Disrupt, Discredit, Divide”


IV.1. Overview

Section III established that the Government conducted a covert, large-scale FBI investigation beginning in 2015, while publicly representing a much later start date. Section IV examines how that undisclosed investigation operated in practice - not only through subpoenas and undercover agents, but through social, psychological, and relational manipulation inside the Sanovas ecosystem.

At the center of this activity was William Gleason, an intelligence-experienced commercial actor operating through Cellmark AB, whose involvement went far beyond ordinary distribution relationships and entered the realm of embedded influence operations.

This section integrates documented conduct with established FBI operational frameworks, particularly the tactic described by former FBI agent Mike German as “Disrupt, Discredit, Divide.”


IV.2. William Gleason: A Documented Intelligence Background

Public records establish that William Gleason spent a substantial portion of his career in foreign intelligence and intelligence-adjacent roles. His obituary, published by a local newspaper of record, the Marin Independent Journal (See DKT 42.1, Exhibit #12), documents decades of service involving international operations, intelligence functions, and overseas commercial activity.

This background is not disputed, nor is it inherently improper. Former intelligence professionals routinely transition into private commerce, advisory roles, and international business. The relevance here is contextual: when intelligence-linked individuals later participate in commercial ventures that become entangled in criminal proceedings, journalists properly ask how those intersections were evaluated.


IV.3. Cellmark AB: Commercial Agreements, Not Informal Contacts

The record reflects that Cellmark AB, a global commodities and distribution company, entered into formal, written distribution agreements relating to Sanovas technologies.

These were not casual introductions or speculative discussions. They were contractual relationships, memorialized in executed agreements that governed distribution, commercialization, and market access.

The existence of these agreements is documented. Their terms are documented. Their timing is documented.

What is not documented in the public record is how these relationships were later characterized - or whether they were characterized at all - during the criminal investigation.


IV.4. From Distribution Partner to Embedded Actor

The record reflects that Cellmark AB was not a passive counterparty. It functioned as a commercial gateway into Sanovas’ internal environment.

Through William Gleason, Cellmark gained:

This access was contractual in origin - but it became operational in effect.

Exhibit #12 (DKT 42.1) confirms that Cellmark’s relationship was formalized. What followed, however, exceeded the role of an arms-length distributor.


IV.5. Temporal Proximity and Litigation Trajectory

Following the criminal indictment of Lawrence J. Gerrans, civil litigation was initiated by William Gleason and related parties, asserting claims that, according to the pleadings, closely tracked the factual allegations later advanced by the government. From an investigative standpoint, this raises several neutral but important questions:

Civil litigation following criminal indictment is not unusual. What draws scrutiny here is the alignment of narratives across civil and criminal forums, particularly where underlying conduct had been contractually authorized and disclosed.

The nexus between Gleason and the governments alignment is reflected most acutely when analyzing the Governments issuance of its amended indictment, on November 8, 2018 – 120 days after the original indictment was issued, which manufactured three (3) additional counts against Mr. Gerrans alleging false statements. This second indictment occurred contemporaneous to the disclosure of Mr. Gerrans Separation and Release from the Company, which required the Company to pay Mr. Gerrans over $1.9 million for accrued and deferred compensation, severance and repayment of loans Mr. Gerrans made to the Company, as well as a Consulting Agreement which enabled Mr. Gerrans to assist the company through litigation.

Charging Mr. Gerrans with making false statements established the probable cause Gleason and the government needed to move the Civil Court to issue a Temporary Restraining Order that blocked the company from paying Mr. Gerrans any of these monies. Thus, the amended indictment perpetuated the governments tortious interference and financial choke-out of Sanovas, Mr. Gerrans and his Family.


IV.6. Intelligence Experience as an Operational Lens

Gleason’s background in foreign intelligence is not speculative; it is publicly documented. Intelligence experience shapes behavior even in civilian contexts - particularly regarding:

These skills are not illegal. But when deployed inside a company already under covert federal investigation, they take on investigative significance. Journalists do not need to infer intent. They need only observe alignment between method and outcome.


IV.7. “Fireside Chats,” Social Grooming, and Investor Manipulation

According to emails, witness testimony, and FBI 302s reflected in the record, Gleason engaged in a series of social-psychological tactics that included:

These gatherings were not incidental. They served as informal intelligence-gathering and influence forums, designed to:


This conduct aligns precisely with the “Divide” phase of the FBI framework described by Mike German in his Book, entitled: 

"Disrupt, Discredit, Divide - How the New FBI is destroying Democracy".


IV.8. Disrupt, Discredit, Divide - Applied

Mike German’s work explains that modern FBI operations - particularly in white-collar and national-security-adjacent matters - often follow a predictable pattern:

In this case, the record reflects:


This is not conjecture. It is methodology documented by a former FBI Agent who executed it, at a time contemporaneous to the attack on Mr. Gerrans and his enterprise, mapped onto conduct that appears in the evidentiary record.


IV.9. Psychological Operations as a Force Multiplier

The social operations attributed to Gleason were particularly effective because they:

By the time formal charges were filed, the internal damage was done. The enterprise was weakened, trust eroded, and leadership isolated. 

Indictment did not begin the collapse. It formalized it.


IV.10. Civil Litigation as Narrative Echo

Following indictment, Gleason participated in civil litigation that closely mirrored the Government’s criminal allegations. From an investigative standpoint, this raises important questions:

Again, these are questions for investigation, not assertions. But they are questions that arise naturally when intelligence-style influence operations precede parallel civil and criminal actions.


IV.11. Why This Matters Systemically

What this section reveals is not a rogue actor, but a systemic vulnerability:

This is precisely the kind of convergence that escapes traditional oversight.

 

 

IV.12. Relationship to Actual Innocence

Crucially, none of this changes the core legal fact:

Authorized corporate governance foreclosed federal jurisdiction ab initio.

What it explains is how a case devoid of jurisdiction survived long enough to cause irreversible harm - through concealment, disruption, and division.


IV.13. Transition

Having now documented covert investigation (Section III) and embedded psychological operations (Section IV), the dossier next examines how intelligence, venture capital, and prosecution increasingly converge in innovation ecosystems - and why this case is not an anomaly.

SECTION V will examine:
 “When Intelligence, Capital, and Law Enforcement Converge.”

SECTION V

WHEN INTELLIGENCE, VENTURE CAPITAL, AND PROSECUTION CONVERGE

How Startup Ecosystems Become Surveillance Environments - and Why Oversight Fails


V.1. Overview

Sections III and IV documented covert federal investigation and embedded psychological operations that predated the indictment of Lawrence J. Gerrans by years. Section V examines the structural convergence that made those operations possible - and largely invisible: the growing overlap between intelligence practices, venture investment, and criminal enforcement within startup and innovation ecosystems.

This convergence does not require conspiracy. It arises from institutional incentives, shared methodologies, and porous boundaries between domains that increasingly operate on the same terrain.


V.2. The Intelligence - Venture Interface Is Institutionalized

The existence of In-Q-Tel, the CIA’s publicly acknowledged venture capital arm, is not controversial. It reflects an institutional recognition that innovation ecosystems are intelligence environments - places where information, technology, and influence converge.

In-Q-Tel’s mandate, as publicly described, is to:

This model has been widely studied and emulated - sometimes formally, sometimes informally. The result is an environment in which intelligence logic enters commercial spaces as routine risk management, not exceptional intervention.

Mr. Gerrans innovations and legislative advocacy in Social Finance and Equity Crowd Funding disrupted In-Q-Tel’s access to the innovation ecosystem inasmuch as it impacted all institutional gatekeepers. In fact, more so.  


V.3. Intelligence Experience as a Governance Presence

Within this environment, it was no longer unusual for former intelligence officials to sit on boards, advise startups, or participate in commercial partnerships.

In the Sanovas case, the record reflects the presence of intelligence-experienced individuals in multiple roles:


Each role is lawful in isolation. The investigative significance emerges from their simultaneity, particularly when paired with a covert federal investigation operating on a concealed timeline.

Coincidentally, the CIA Employee, Rick Wyatt, and William Gleason knew of Mr. Gerrans indictment before Mr. Gerrans was ever informed of it. This is evidenced by their phone calls to Sanovas investors and personnel informing them of Mr. Gerrans indictment to sow the seeds of doubt and initiate their psycho-social influence campaign.


V.4. From Risk Assessment to Information Extraction

Intelligence frameworks prioritize:


When these frameworks migrate into startup environments - especially under the guise of partnership or investment - they can reframe ordinary business friction as investigative signal.

In this case, the Government’s undisclosed 2015 Google grand jury subpoena seized:


This was not targeted discovery. It was wholesale data extraction, consistent with intelligence collection methods, later repurposed within a prosecutorial narrative.


V.5. The Prosecutorial Absorption of Intelligence Methods

By the time the case reached charging and trial phases, intelligence-style methods had already done their work:


At that point, prosecution became the final administrative step, not the initiating act. This sequencing explains why courts later struggled to reassert control: the real adjudication had already occurred - in markets, relationships, and narratives.


V.6. Oversight Failure at the Convergence Point

Traditional oversight mechanisms assume clear boundaries:


But when these domains overlap, no single institution owns accountability.

In this case:


Oversight failed not because of malice, but because no actor was positioned - or incentivized - to stop the process once it began.


V.7. Why This Convergence Endangers Innovation

For founders and innovators, this convergence creates a structural hazard:


The system is optimized for control, not correction.


V.8. Why This Case Is a Bellwether

This case matters beyond its facts because it:


It is not an aberration. It is a case study.


V.9. Transition

With Sections I–IV complete, this dossier now explains:


What remains is synthesis - for readers, editors, investigators, and policymakers.

SECTION VI - THE CORPORATE RAID THAT FOLLOWED THE INDICTMENT

How “Rescuers” Became Raiders, a Life’s Work Was Hollowed Out, and the Company Was Stripped from the Inside


VI.1. The Vacuum After Indictment: When Survival Overrides Scruple

When the indictment issued, Sanovas did not merely face a legal crisis. It entered a governance vacuum.

Capital access vanished overnight. Banking relationships froze or constricted. Investors panicked - not because a court had found wrongdoing, but because markets and lawyers understand what an indictment does to a company’s survivability. The founder, already isolated by the Government’s actions, became radioactive in the eyes of counterparties whose risk tolerance was governed by regulation, not presumption of innocence.

It is in precisely this moment - when an enterprise is destabilized but not yet dead - that opportunists appear.


VI.2. June 28: The Arrival of the “Rescuers”

On June 28, just 14 days before the indictment, two men were introduced into the Sanovas ecosystem:


They were presented as seasoned Wall Street broker-dealers - older, experienced figures who claimed they could “open doors” in the capital markets that the founder could not. Their pitch was credibility, access, money, and rescue.

The timing is impossible to ignore. Sanovas was on the brink of a regulatory and reputational cliff. The founder was under extraordinary pressure. The company was desperate for capital, legitimacy, and reassurance.

Katzman and Bayern offered all three. What they ultimately delivered was something else entirely.


VI.3. From Rescuers to Raiders

In the immediate aftermath of the indictment, as the founder was pushed - by investors, counsel, and circumstance - to step aside “for the good of the company,” Katzman and Bayern positioned themselves not as temporary stewards, but as successors. This is where the narrative turns.

 Instead of stabilizing Sanovas:


What followed bears the hallmarks of corporate raiding, not corporate rescue.


VI.4. The Quiet Destruction of Intellectual Property

The most devastating act did not involve a lawsuit, a vote, or a public announcement. It involved inaction.

Sanovas’ value resided overwhelmingly in its intellectual property - hundreds of patents and applications representing decades of innovation. Maintaining those patents required nothing more than the timely payment of routine maintenance fees. Those fees were not paid.

As a result, core patents and trademarks expired, one by one, extinguishing the company’s technological moat and erasing the founder’s life’s work without:


This was not a market loss. It was a preventable annihilation.


VI.5. Profiting From the Wreckage

While the parent company withered Steve Bayern emerged as an insider, engaging in stock transactions netting him millions of dollars and collecting consulting fees without producing transparently documented work product commensurate with those payments. 

At the same time Jerry Katzman installed himself as CEO of Sanovas and all of its subsidiaries, consolidating authority over the company while shuttering facilities, terminating employees and allowing core assets, patents, and trademarks to lapse quietly. 

Original investors - the people who funded the innovations - were abandoned. The founder and his family were abandoned. Katzman conducted a defamation campaign to slander the Executive among shareholders - whom he had formerly praised as a genius, and initiated false and misleading Board and Legal maneuvers to strip Mr. Gerrans and his Family of all of their stock – to continue to perpetuate the financial choke-out. Leaving Mr. Gerrans wife and children, whom Katzman pledged to stand by - "shoulder to shoulder", to be left destitute and thrown out of their childhood home in the midst of the COVID pandemic. The enterprise that had been presented as “rescued” was, in reality, being stripped for parts, and the lifeblood that built it were not only abandoned they were ripped off. 

This is not conjecture. It is a pattern reflected in corporate records, patent histories, and trading activity.

 

VI.6. The Intelligence Echo: A Board Seat That Raises Questions

Adding to the gravity of this transformation is the presence of Rick Wyatt, a retired CIA employee, who among the first to know about Lawrence Gerrans indictment, and who became immediately seated on Sanovas’ Board of Directors. This fact is not presented as proof of conspiracy. It is presented as context.

In a case where intelligence-linked commercial actors (Cellmark) appear earlier in the investigative timeline, covert operations and narrative warfare are documented elsewhere in the record, and a founder-led company is dismantled following federal action, the placement of a retired intelligence professional in the boardroom of the remnants of that company raises legitimate questions about ecosystem convergence - how intelligence, capital, and prosecution intersect in high-stakes innovation environments.

Editors should ask:


VI.7. Betrayal as a Structural Outcome

It would be comforting to view this as a story of bad actors. That would be incomplete. The deeper truth is more unsettling: 

The system creates conditions where betrayal becomes rational. 

Once the founder was neutralized by indictment and financial choke-out:

The Government did not have to seize the company. It merely had to remove the person who embodied it. Others did the rest.


VI.8. Why Section VI Matters

Section VI answers the second half of the WHY question:

Why does government overreach matter even after indictment?

Because when enforcement actions destabilize an enterprise without adjudication, the private market will complete the punishment - often more ruthlessly and irreversibly than any court.

The destruction of Sanovas did not occur in a courtroom. 

It occurred in boardrooms, back offices, bank desks, and patent offices - out of public view.

 

VI.9. Transition to Section VII

Section VII will show that this was not merely opportunism following chaos, but chaos engineered through concealment. It will expose:


Only then does the full architecture of this campaign come into view.

 

SECTION VII  - THE SYSTEMIC PATTERN AND THE PRECEDENT THIS CASE ESTABLISHES

How This Case Reveals a Repeatable Model for Destroying Innovation Without Adjudication

Why the Prosecution of Lawrence J. Gerrans Threatens Corporate Governance, Innovation, and Capitalist Democracy


At its core, the prosecution of Lawrence J. Gerrans is not about one man, one company, or one controversial set of business decisions.

It is about what happens when the federal criminal system is allowed to override corporate governance, ignore jurisdictional limits, and rely on institutional inertia to preserve a conviction that should never have occurred.


VII.1. From One Case to a Pattern

Taken in isolation, the destruction of Sanovas could be misread as a tragedy - a hard case with unfortunate collateral consequences.

Taken together, the record assembled in Sections I through VI reveals something far more consequential: a repeatable model.

This model does not rely on convictions.
 It does not require proof beyond a reasonable doubt.
 It does not depend on judicial findings at all.

It operates through process, not verdicts.


VII.2. The Model, Step by Step

The pattern revealed by this case unfolds in a recognizable sequence:

Entrapment, bond revocation, incarceration, isolation, disconnection, dis-communication, transportation, deconditioning and litigation paralysis ensure the target cannot mount a defense and then escalate the process after conviction to procedurally bar appellant’s defensive options.  


This sequence does not require coordination across every step. It only requires institutional tolerance for opacity and omission.


VII.3. Why This Pattern Is So Dangerous

The danger lies not in any single tactic, but in their cumulative effect. Each step is defensible in isolation:


But when combined - and shielded from transparency - these steps substitute process for adjudication.

The result is punishment without trial.


VII.4. The Illusion of Accountability

One of the most insidious features of this pattern is that it appears accountable. There is a case number. There are filings. There are hearings. But the decisive actions occur:


By the time appeals are heard, the company is gone, the patents expired, the founder ruined, the investors dispersed. The Courts are never allowed to hear the facts of the case because evidence discovered after the fact becomes procedurally barred and a bad conviction is made to stick.

The system can declare itself complete - without ever resolving the merits.


VII.5. Why Innovators and Boards Should Be Alarmed

This case does not merely threaten founders. It threatens corporate governance itself. If unanimous board authorization, preferred stock rights, and documented management authority can be recharacterized as criminal after the fact - then boardrooms are no longer safe spaces for decision-making.

Every director, officer, and investor must then ask:

Are we governing, or are we merely one indictment away from destruction?


VII.6. The Constitutional Dimension Revisited

The Constitution’s promise to inventors was not abstract. It was designed to encourage risk-taking by protecting the fruits of innovation.

When innovators can be removed from the market not by competition, not by regulation, and not by adjudication - but by concealed investigation and regulatory weaponization - that promise collapses.

Innovation becomes a liability.

That is not a market failure. It is a constitutional one.


VII.7. Why This Is a Legislative Story Now

Congress is currently examining allegations of political and institutional weaponization within the Department of Justice and related agencies. This case provides:


It is not speculative. It is retrospective - and therefore safe to investigate.

The question is no longer “Did this happen?” It is “Will it be allowed to happen again?”

 

VII.8. What Oversight Must Address

If legislators take this pattern seriously, several oversight questions follow naturally:


These are not partisan questions. They are structural ones.


VII.9. The Precedent Shift: From Governance to Prosecution

For more than a century, American corporate law has rested on a clear division of authority:


The Gerrans case, as documented in the record and filings, represents a decisive break from that structure. If this prosecution stands, it establishes a precedent in which:


In effect, the case collapses the distinction between a bad business decision, and a federal felony. That distinction is foundational to capitalist enterprise.


VII.10 Indictment as Corporate Death Sentence

One of the most underreported realities of white-collar prosecution is this:

Indictment alone is often fatal to a company.

Even without conviction:


In the Gerrans case, this destruction occurred before any lawful adjudication of guilt, and - according to the defense - despite the absence of criminal conduct. If indictment can be used to dismantle a company, and displace an innovator, without lawful jurisdiction, then the criminal process itself becomes an instrument of market intervention.

That is not law enforcement. It is economic power exercised without democratic accountability.


VII.11. Chilling Effect on Boards and Executives

The precedent set here does not merely affect founders. It directly affects:


If unanimous board authorization does not protect directors and officers from criminal exposure, then rational actors will respond predictably:


The result is not safer governance. It is paralyzed governance.


VII.12. The Innovation Death Penalty

Innovation depends on three things:


The Gerrans prosecution, if upheld, undermines all three.

Innovators operating in regulated industries - healthcare, biotech, finance, energy, mining - will be forced to assume that success invites scrutiny, and scrutiny may escalate into prosecution, even absent wrongdoing

This creates what economists describe as a negative innovation externality: society loses not because innovation failed, but because it was never attempted.

 

VII.13. Capital Flight and Selective Enforcement

Capital is not patriotic. It is rational. When legal systems become unpredictable, capital migrates:


If the federal government can intrude into boardrooms and criminalize authorized governance, investors will demand higher returns to offset legal risk or completely withdraw from innovative enterprises. This disproportionately harms:


The result is selective enforcement by market attrition, not by law. Inevitably capital and talent exits the market and eventually the country.


VII.14. Separation of Powers and Democratic Accountability

Perhaps the most troubling precedent established by this case lies not in corporate law, but in constitutional structure. When:


The separation of powers ceases to function.


The executive branch effectively gains:


This concentration of power is precisely what the Constitution was designed to prevent.


Innocence Becomes Irrelevant

The ultimate consequence of this precedent is stark: Innocence becomes irrelevant. If:


then the outcome of a case depends less on law and more on endurance.

Justice becomes a test of survival. To the point, Mr. Gerrans has now endured eight (8) years of legal bureaucracy simply trying to prove his actual and factual innocence. Meanwhile, his 250+ Multi-national Patents and Trademarks have expired, the promise of his Life’s Work has been extinguished and his family’s life and good name decimated and bankrupted – all because this weaponization has gone unchecked.


VII.15. Why Journalists Matter Here

Why This Is an important Story for Journalists

This is not merely a legal appeal. It is a story about:


It is also a story with documents, timelines, and verifiable claims - now augmented by newly disclosed evidence before the Ninth Circuit. You do not need to resolve every allegation to publish this story.

You need only answer one question:

Did a prosecution that lacked jurisdiction nevertheless destroy a lawful enterprise - and could it happen again?


You are not being asked to adjudicate guilt. You are being asked to illuminate process. This dossier does not demand belief. It demands examination.

If the pattern holds under scrutiny, then the implications extend far beyond one company or one founder. They extend to the future of innovation, capital formation, constitutional governance and the free market principles that built the United States into the strongest economic power in history.


VII.16. The Call to Investigate

This dossier does not ask you to advocate. It asks you to investigate.

To examine:


If the answer to any of these questions is yes, the implications are immediate and national.


VII.17. The Final WHY

At its core, this case asks a question that cannot be ignored:

Can the American system tolerate a method by which innovators are destroyed without trial, governance is criminalized after the fact, and courts are prevented from intervening until nothing remains to save?

If the answer is no, then this story must be told.

This is not an appeal for sympathy.

It is a call for accountability.


Conclusion

The prosecution of Lawrence J. Gerrans presents a simple but urgent challenge to the rule of law:

Can the federal government criminalize authorized corporate governance - and rely on judicial inaction to make it stick?

If the answer is yes, then the risk is not confined to one defendant or one company.

It extends to every boardroom, every founder, and every investor operating under the assumption that lawful governance is a shield against criminal sanction.

This dossier exists so that assumption can be tested - before the precedent hardens beyond repair.
 

SECTION VIII – Sources and Exhibits

Sources (Publicly Available)

USA v. Lawrence J. Gerrans, 3:18-cr-00310EMC, 9th Circuit, Northern District, San Francisco, Original Criminal Case [See Post-conviction pleadings (See DKT 235, 435, 477, 501-517, et al)]

USA v. Lawrence J. Gerrans, 0:20-cr-10378, 9th Circuit Court of Appeals, San Francisco, Direct Appeal [See Int’l Trade Judge M. Miller Baker’s Dissenting Opinion at DKT 46].

 

Lawrence J. Gerrans v. USA, 3:23-cv-00801, 9th Circuit, Northern District, San Francisco, Motion to Vacate, Set Aside conviction pursuant to 28 USC §2255. Original §2255 Petition.

 

USA v. Lawrence J. Gerrans, 0:24-cr-06740, 9th Circuit Court of Appeals, San Francisco, Appeal of Motion to Vacate, Set Aside conviction pursuant to 28 USC §2255.


Gonzalez et al. v. Ahern et al., 3:19-cv-07423, 9th Circuit, Northern District, Oakland, Civil Case regarding Pre-Trial Punishment, Conditions of Confinement.

USA ex rel. Lawrence J. Gerrans v. U.S. D.O.J, et al, 1:26-cv-00208, District of Columbia, District Court, Verified Complaint for Violations of the False Claims Act, 31 USC §§3729-3733

Lawrence J. Gerrans v. U.S. D.O.J, et al., 1:26-cv-00170, District of Columbia, District Court, Verified Complaint for Declaratory and Injunctive Relief, Administrative Procedures Act, 5 USC §§ 701-706.

Lawrence J. Gerrans, ex rel. v. Robin Harris, et al, 1:24-cv-00933UNA, District of Columbia, District Court, Verified Complaint for Violations of the False Claims Act.

Lawrence J. Gerrans v. U.S. Department of Justice, et al, 1:24-cv-01252UNA, District of Columbia, Petition for Relief pursuant to 5 USC §§701-706 of the Administrative Procedures Act.

Lawrence J. Gerrans v. Erhan Gunday, et al., 3:24-cv-02187, 9th Circuit, Northern District, San Francisco, Civil RICO Complaint.

Lawrence J. Gerrans v. Erhan Gunday, et al., 3:25-cv-00331, 9th Circuit Court of Appeals, San Francisco, Appeal Civil RICO Complaint.

 

Exhibits (Provided Upon Request)

Exhibit A: Unanimous Written Board Consent(s) (redacted)
 Exhibit B: Delaware authority (DGCL §141; §141(f) excerpt)
 Exhibit C: Charging documents excerpts (indictment theory)
 Exhibit D: District court threshold motions and rulings (as available in Docket)
 Exhibit E: Ninth Circuit opinions, memo, partial dissent (as available in Docket)
 Exhibit F: Detention/transfer timeline (records, logs, declarations)
 Exhibit G: Iron Mask excerpts (redacted; dated entries where possible)
 Exhibit H: Dark Pharma context excerpts (market impact narrative)
 Exhibit I: Oversight brief / APA / FCA filings (relevant sections)
 Exhibit J: Mike German framework references (publisher/event sources)
 Exhibit K: Stone v. Ritter; Disney (excerpts)

Exhibit M: U.C. Berkeley Case Study

Exhibit N: Investigative Dossier: The Prosecution of Lawrence J. Gerrans (Legal Case Study)

 

Please make inquiries to Lawrence J. Gerrans directly at:

(928) 622-1140

protectcorpboardrooms@protonmail.com